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Abstract
Background: Gestational diabetes mellitus (GDM) increases the risk of adverse short- and long-term outcomes,
including development of type 2 diabetes. The US Diabetes Prevention Program demonstrates this risk can be
halved with an intensive health behavior change intervention in women with pre-diabetes averaging 12 years
since a GDM pregnancy. In recent years, the number of studies looking at changing the behaviors of women
with previous GDM closer to the time of delivery has steadily grown, but reported outcomes vary and most
studies are not long enough or large enough to examine incident diabetes. This initiative aims to develop a
core outcome set (COS) for interventions seeking to prevent diabetes after pregnancy (DAP) in both women
with prior GDM and their families.
Methods: The COS-DAP project will use established COS methodology, in four stages: (1) a systematic literature
review of DAP prevention intervention studies following GDM; (2) discussion and cataloguing of outcomes
measured and implementation components at an investigator meeting; (3) a two-round online Delphi survey
aimed at prioritizing the identified outcomes; and (4) a consensus meeting with key stakeholders to review, discuss,
and refine suitable COS measures, using nominal group technique.
Discussion: COS-DAP aims to develop a COS for health behavior change interventions to prevent DAP. The
COS is expected to enhance opportunities for comparison of future studies and allow for better synthesis of
the effects. The inclusion of multiple stakeholder perspectives will increase the final COSs applicability and
relevance.
Trial registration: Comet Initiative, COMET 1083; PROSPERO, CRD42018084853. Registered in prospero on 03/01/2018.
Keywords: Gestational diabetes, Diabetes prevention, Core outcome set, Behavior change interventions
Background
Gestational diabetes mellitus (GDM) is one of the most
common pregnancy complications affecting around 5–15%
of pregnancies [1–3]. Studies show that GDM increases the
risk of adverse short- and long-term health outcomes in
both the woman and her offspring. A previous meta-ana-
lysis reported that women with a history of GDM had a
sevenfold increased risk of developing type 2 diabetes [4]. A
more recent meta-analysis suggests that the adjusted risk is
18-fold higher [5]. Offspring of women with GDM are also
at elevated risk of developing diabetes [6] and we have
demonstrated that GDM in mothers predicts incident dia-
betes in fathers [7]. Thus, developing effective interventions
is imperative as these interventions have the potential to
have a lasting impact on the health of the whole family.
While few have intervened at the family level, the evi-
dence from the US Diabetes Prevention Program (DPP)
trial indicates that intensive health behavior change
intervention can reduce the progression to diabetes by
58% in women with a GDM history [8]. These women
were however an average of 12 years after their first
pregnancy complicated by GDM and had already devel-
oped impaired glucose tolerance, indicating they were
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further along the GDM to diabetes trajectory. In contrast,
the majority of diabetes after pregnancy (DAP) occurs
during the first five postpartum years [9]. Our recent co-
hort study demonstrates that among women who develop
DAP, the median time to DAP after GDM was approxi-
mately five years compared with 10 years in women with-
out GDM or gestational hypertension [10]. These early
postpartum years present women with additional chal-
lenges through the combined pressures of new mother-
hood and work-related responsibilities [11–13], which can
result in lower prioritization and less perceived time for
engagement in DAP prevention activities.
In the years following the US DPP, many investiga-
tors have conducted DAP prevention studies focusing
on women during pregnancy or within the first five
years, with an eye to aligning intervention frequency,
intensity, and design to the day-to-day realities of life
with a young family [14]. Unfortunately, the reported
outcomes from these studies differ widely and the lack
of consistency limits the understanding of behavior
change mechanisms and intervention effects. The
amount of information recorded on the wider context
in which the intervention is implemented is limited as
is use of theoretical frameworks for behavior change.
Consequently, it remains unclear which outcome mea-
sures are the most important to include in health
behavior change intervention studies, whether these
outcomes should be adapted as the woman and her
family grow older, and which contextual factors influ-
ence intervention effectiveness.
The development of a core outcome set (COS) for health
behavior change interventions in women with previous
GDM is urgently needed. A COS is a standardized set of
outcomes to be reported across all trials within a specific
area [15]. The importance of developing COSs is specific-
ally promoted within the CROWN initiative led by the edi-
tors of more than 80 journals aiming to harmonize
outcome reporting for women’s health, thus enabling more
effective evidence synthesis (http://www.crown-initiative.
org/journals/) [16]. Our project seeks to develop a COS for
intervention studies with the objective of DAP prevention
in women with prior GDM and their families.
Methods
The COS-DAP project was launched in October 2017
and adheres to the Core Outcomes Measures in Effective
Trials (COMET) initiative and the Core Outcome Set –
Standards for Reporting (COS-STAR) statement [17].
The study has been registered in COMET (1083) and
has four stages (Fig. 1):
1. A systematic literature review to identify core
outcomes in DAP prevention interventions and
contextual indicators that may influence both
recruitment and impact;
Fig. 1 Core set of outcomes development overview for COS-DAP project
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2. A discussion and outcome clarification meeting to
inform the Delphi survey;
3. A two-round Delphi survey to prioritize the identi-
fied outcomes and contextual indicators; and
4. A nominal group technique consensus meeting with
key stakeholders to identify the COS and refine
suitable measures to assess them.
Stage 1: Synthesis of health behavior change intervention
outcomes
The identification of the outcomes will be conducted via
systematic literature review of the existing literature.
Search strategy
The search will use the electronic databases Embase,
OVID Medline, CINAHL, Cochrane Central Register of
Controlled Trials, and Cochrane Pregnancy and Child-
birth Group Trials Register. A combination of a number
of terms, including MeSH terms, will be employed,
including “gestational diabetes” and/or “diabetes in preg-
nancy,” “postpartum period,” “diabetes reduction,” and/
or “diabetes prevention,” as well as terms related to the
intervention (e.g. “diet,” “body mass index,” “weight
reduction,” “exercise,” “health behavior change,” “cogni-
tive therapy”). The search will be limited to published
literature and English language, but there will be no
restrictions in terms of publication date or study inter-
vention type. The systematic review has been registered
at PROSPERO (CRD42018084853). The PROSPERO and
COMET websites were searched to identify potentially
similar research and determine the applicability of the
search strategy. A single COMET study was sufficiently
similar to contact the lead investigator (reference no.
686); however, following discussion, the investigators felt
the focus of the COS was sufficiently different to merit
the COS-DAP project continuing.
Study selection, eligibility, and data extraction
Eligible studies will report outcomes in the postpartum
period in women with a history of GDM and/or their ex-
tended family. Outcomes related to the infant or father
will also be selected for review. In order to be eligible
for inclusion, studies have to be randomized controlled
trials (RCT), pre- and post-intervention studies, multi-
center studies, clinical trials, comparative studies, evalu-
ation studies, and intervention protocols. Reviews, case
reports, meta-analysis, systematic reviews, observational
studies, letters, guidelines, commentaries, historical articles,
and editorials will be excluded. Interventions designed to
change health behaviors such as diabetes screening and life-
style outcomes will be included, whereas studies focusing
on pre-pregnancy GDM outcomes, pharmacological treat-
ments, or supplement trials will be excluded.
Two reviewers will independently screen all articles by
title and abstract. Full-text articles will be reviewed in
duplicate as a minimum to determine whether suitable
for inclusion. Data will be abstracted and recorded on a
standardized form. Any disagreement on the eligibility at
any stage will be resolved through discussion and con-
sensus with the research team. The Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) guideline will be followed in the documenta-
tion of the process.
The types of contextual data recorded will be guided
by the Penetration, Implementation, Participation, and
Effectiveness (PIPE) framework and the Context and Im-
plementation of Complex Interventions (CICI) frame-
work [18, 19]. PIPE is designed to evaluate real-world
program and product design elements; as such, it is use-
ful a guide to assess the net impact of health improve-
ment programs [18] and thus to increase the relevance
of our findings to policy and practice. There are three
dimensions within the CICI framework [19]. Three levels
exist for any domain: macro, meso, and micro; these can
be used to add relevant detail to a domain. The extent of
the usefulness of the CICI and PIPE frameworks data
will be evaluated at stage 2 and may or may not be in-
cluded in subsequent stages pending this evaluation.
Data analysis
The characteristics of each included study will be pre-
sented in tables and descriptively. Outcomes will be di-
vided into domains based on thematic exploration of the
outcomes identified and grouping them thematically to
represent overarching categories. For example, we expect
several measures of diabetes risk to be outcomes. The
stage 2 process will see these outcomes narratively syn-
thesized into a long-list of health behavior change inter-
vention outcomes and their associated measurement
tools or contextual factors where relevant. Analyses re-
lated to the outcomes, the context, the process, and the
behavioral change frameworks are planned. The exact
identification of domains and categorization of outcomes
and contextual factors will be agreed upon during the
discussion meeting in the next stage of the development.
Stage 2: Investigators meeting
The meeting will enable a roundtable discussion among
the members of the research team on the systematic re-
view findings and clarification of identified outcomes
and outcome domains. The participants at this meeting
(SOR, KD, KKN, HTM) will involve representation
from the following stakeholder groups: public health;
health promotion; dietetics; and internal medicine. For
this meeting, all the outcomes identified in the system-
atic review will be listed and the grouping into domains
will be discussed and executed. Outcomes related to
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the mother, father, and child will be discussed separ-
ately in addition to considering biological, behavioral,
health outcomes, and contextual measures. Further, the
strength of the evidence and the knowledge gaps will
be reviewed and discussed.
The meeting will also be used to plan the e-Delphi sur-
veys, including the development and refinement of ques-
tion stems relevant to each section. Once these have been
drafted, they will be consolidated into final draft surveys.
Stage 3: e-Delphi survey
In order to prioritize the outcomes and contextual fac-
tors identified during stages 1 and 2, an e-Delphi tech-
nique will be applied. The Delphi survey is a technique
that collects the opinions of relevant stakeholders to ar-
rive at a consensus on a topic. Its use is common in the
development of COS; the e-Delphi version allows for the
process to be carried out online thus enabling greater
international participation. The method involves asking
stakeholders to complete two or more rounds of the
same survey, in which stakeholders rate the importance
of each outcome and factor. After each round, the re-
sponses are tabulated and redistributed to the partici-
pants. The intention is that the iterative process will
facilitate consensus on the most important outcomes.
In this project, two rounds of Delphi surveys will be
conducted. The DelphiManager software developed by
the Core Outcome Measures in Effectiveness Trials Ini-
tiative (Liverpool, England - http://www.comet-initiative.
org/delphimanager/) will be used to conduct the e-Del-
phi rounds and analysis.
Participants
The panel of participants in the Delphi surveys will con-
sist of three stakeholder groups: (1) women with current
or prior GDM; (2) healthcare/public health professionals;
and (3) researchers. The recruitment of women with
current or prior GDM and professionals will primarily
be from Australia, Canada, Denmark, the United King-
dom, and Ireland, whereas recruitment of researchers in
the area will have a broader geographical focus, aiming
to include participants globally.
Potential stakeholders will be identified through the
most appropriate contact methods for each stakeholder
group. For women with current or previous GDM, we
will use online parenting forums (e.g. www.eumom.ie,
www.babycentre.com), clinics, and social media. For
healthcare professionals, we will use national and inter-
national professional associations (e.g. Irish Nutrition
and Dietetic Institute, Diabetes Canada, The Danish Dia-
betes Association.) Healthcare professionals will be wel-
come to invite current or former patients with GDM to
also participate in the survey. For researchers, we will
use international research organizations and networks
(e.g. Health Research Board Mother and Baby Network,
Diabetes Canada, International Federation of Gynaecol-
ogy and Obstetrics [FIGO]). Corresponding authors of
relevant publications from stage 1 will also be contacted.
Participants will be invited to participate in the Delphi
surveys via email. Delphi surveys typically involve 20–50
participants, with lower numbers for more homogeneous
groups, but we will be taking into account factors such
as attrition, contexts, and diversity of responses. We aim
to invite at least 150 participants to the Delphi surveys
and at least 20 participants in each stakeholder group.
Informed consent will be obtained from participants at
the time of registration onto the online questionnaire. Par-
ticipants will be informed of the study objectives, their right
to withdraw, and that data will be handled with confidenti-
ality and anonymized. They may also have any questions
answered before registration and consent through a dedi-
cated email address. The importance of participation
throughout the whole Delphi process will be emphasized
and two email reminders will be sent to non-responding
registered participants in each round. The software system
will assign each participant a unique identifier allowing for
the follow-up and monitoring of attrition throughout the
e-Delphi survey rounds.
Procedures
On the registration form, participants will be asked to
provide information about the relevant stakeholder
group or groups applying to them, as well as demo-
graphic information such as age group and ethnic back-
ground. On the home page of each Delphi round,
participants will be provided with plain language sum-
maries on COSs and the Delphi process. Throughout
the survey, plain language definitions of each outcome
are also provided. Health professionals and researchers
will be invited to complete the survey in English.
Women with current or prior GDM will have the option
of completing the survey in English, French, or Danish.
Round 1
In the first Delphi survey round, the full list of outcomes
is provided to the participants, who will be asked to pro-
vide a score for each outcome. Participants will be asked
the question “How important do you think each out-
come is to measure in lifestyle interventions to prevent
diabetes in women with previous gestational diabetes?”
The grading of outcomes is based on the Grading of
Recommendations, Assessment, Development, and Eval-
uations (GRADE) working group [20] and will be on a
scale of 1–9; a score of 1–3 represents a lack of import-
ance, a score of 4–6 represents an outcome that is im-
portant but not critical, and a score of 7–9 represents a
critical outcome. If participants do not feel able to score
an outcome, there is an option to select “Unable to
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Score.” Outcomes will be listed by domain. At the end
of round 1 of the survey, participants also have the op-
portunity to suggest additional outcomes that they deem
important, but that are not already listed on the survey.
Participants will be given three weeks to complete the
questionnaire. Non-responding participants will receive
a reminder email at the beginning of week 2 and week 3.
Analysis round 1
The responses from the first round will be collated and
summarized using descriptive statistics. The distribution
of each outcome score will be computed for the whole
Delphi survey and for each individual stakeholder group.
Any additional outcomes suggested by participants will
be reviewed and discussed by the research team. Out-
comes suggested in round 1 that are not part of the ori-
ginal list will be included in the second e-Delphi round
together with all the outcomes ranked in the first round.
Round 2
Only first round participants will be invited to complete
a second survey. They will be presented with the sum-
marized scores for each outcome stratified by stake-
holder group and the number of respondents for each
score and group. In addition, they will be reminded of
their own round 1 score for each item. They will be
asked to consider the presented information and invited
to rescore each outcome. Changes made to the scoring
will be recorded. Any outcomes added after the first
round will also be presented and participants asked to
score these.
Analysis round 2
In the analysis of the second Delphi survey round, the
number of participants will be documented and the data
will be collated and summarized using descriptive statis-
tics. Distribution of scores will be computed for each
outcome and stakeholder group. Determination of con-
sensus for each outcome, by stakeholder group, will be
based on definitions used in other COS studies [21–24].
Specifically, it will be defined as ≥ 70% participants scor-
ing 7–9 and < 15% scoring the outcome as 1–3. Consen-
sus that the outcome should not be included in the COS
will be defined as 70% of participants scoring the
outcome as 1–3 and < 15% giving it a score of 7–9. Out-
comes for which the distribution of scores differs from
this will be classified as “no consensus achieved.”
Stage 4: Consensus meeting
The face-to-face consensus meeting will be held follow-
ing completion and analyses of the Delphi survey. The
meeting will be held in Halifax, Canada preceding the
Diabetes Canada Meeting in October 2018. Participants
will include the Co-Principal Investigators (KD, SOR,
HTM) respectively from Canada, Ireland, and Denmark
as well as internationally recognized GDM clinicians and
researchers from Australia (Dr David McIntyre), the
United States (Dr Rhonda Bentley-Lewis), and a con-
venience sample of GDM clinicians, researchers, and
women with current or prior GDM representatives from
across Canada.
Procedures
Before the consensus meeting, participants will be pro-
vided with a plain language printed summary of the
COS process, the results of the systematic review, a list
of all of the original and additional outcomes included
in rounds 1 and 2 of the Delphi survey, and the results
of the survey (i.e. consensus for inclusion, consensus for
exclusion, no consensus; analyses by stakeholder group).
This will be followed by a roundtable discussion about
the outcomes, the key context and setting attributes
identified, including their importance and how to meas-
ure these. The roundtable discussion will be conducted
in a neutral manner with all outcomes included. Follow-
ing the discussion, participants will rate every outcome
for inclusion (yes or no rating). Any outcome with > 70%
“yes” rating will then be discussed before a final rating of
outcomes for the COS. The outcomes that receive > 70%
“yes” rating in the final ranking will be included in the
final outcome set.
Discussion
With the current lack of a COS for diabetes after preg-
nancy prevention studies, the development of a COS will
enhance opportunities for comparison of future studies
and allow for better and larger meta-analyses of the
effects. Furthermore, a COS is expected to provide a
better understanding of the health behavior change
mechanisms used in trials and enhance the quality and
assessment of studies by reducing risk of bias and im-
proving reporting. The COS-DAP project will develop a
COS for the evaluation of health behavior change inter-
ventions seeking to prevent DAP, focusing not only on
the affected women’s health, but also the health of their
children and spouses. The work will be carried out in a
close collaboration with researchers from at least three
countries and with the involvement of multiple stake-
holders, including healthcare professionals, public health
experts, women with prior GDM, and researchers. The
inclusion of the perspectives of multiple stakeholders
through their involvement in the e-Delphi and consen-
sus meetings increases the chances of the final COS be-
ing both applicable and relevant (Additional file 1).
Trial status
This is an expanded version of the first protocol, which was
written to obtain funding from the Canadian Institutes of
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Health Research. Further protocol modifications will occur
if logistical considerations mandate these but will require
consensus among the three PIs (SOR, KD, and HTM).
Stage 1 (systematic review) and stage 2 (investigators meet-
ing) of the study have been completed and the first round
of the e-Delphi began July 2018. The second round of the
e-Delphi is expected to be completed by October 2018.
The systematic review led to an evaluation of the penetra-
tion and participation (PIPE) of completed DAP prevention
studies following GDM that report on these PIPE compo-
nents, which was published early online in April 2018 [25].
Additional file
Additional file 1: SPIRIT 2013 Checklist. (DOC 123 kb)
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